Market Forecast by Regions and Countries (North America, Europe, LATAM, Middle East, Asia Pacific and Africa), By Product (Dukoral, Shanchol, Vaxchora, Euvichol & Euvichol-Plus, Others), By End User (Hospitals & clinics, Research & Academic Laboratories, Others) And Competitive Landscape
Product Code: ETC13190265 | Publication Date: Apr 2025 | Updated Date: Jul 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Summon Dutta | No. of Pages: 190 | No. of Figures: 80 | No. of Tables: 40 |
According to 6Wresearch internal database and industry insights, the global cholera vaccine market is expected to grow from approximately around USD 565 million by 2031, at a compound annual growth rate CAGR of 6.9%.
Report Name | Global Cholera Vaccine Market |
Report Category / Coverage | Global |
Forecast Period | 2025 - 2031 |
CAGR | 6.9% |
Market Size | USD 565 million by 2031 |
Growing Sector | Governments |
The Global Cholera Vaccine Market report thoroughly covers the market by Product, End User and Regions. The market report provides an unbiased and detailed analysis of the ongoing market trends, opportunities/high-growth areas, and market drivers, which would help the stakeholders to devise and align their market strategies according to the current and future market dynamics.
The global cholera vaccine market growth has been boosted due to the cholera, a serious waterborne disease, by the emergence and distribution of vaccines as which help to prevent the disease. Vaccines used in both routine immunisation efforts and emergency outbreaks are used in this market. In underdeveloped regions with limited access to sanitation and clean water, multiple organisations like Governments, health, and private companies aligned together to safeguard extensive accessibility. Reducing the global influence of cholera outbreaks and enhancing vaccine efficiency have been driven by active development and research.
The Global Cholera Vaccine Market is expected to grow at a significant CAGR of 6.9% during the forecast period 2025-2031. Factors like growing awareness of preventive healthcare, increasing cholera outbreaks, and growing government and NGO initiatives to enhance public health are supporting the global cholera vaccine market expansion. The vaccine demand is also expanding due to limited access to sanitation and clean water in numerous areas. Furthermore, both production abilities and advancements in vaccine technology align with efforts to improve vaccination distribution in underdeveloped areas, further supporting the growth of the market. Continuous international health collaborations have been fueling the distribution and accessibility of cholera vaccines globally.
The global cholera vaccine market faces several challenges, even with the steady growth in both developing and underdeveloped regions. Limited access to vaccines in low-income regions due to high distribution costs is one of the major issues. In isolated areas, the distribution of the vaccine is hampered due to inadequate healthcare infrastructure. The adoption of the vaccine is hindered by a lack of awareness and vaccine uncertainty. Additionally, to tackle these challenges, the active growth of more accessible and affordable vaccines adds complexity to ensure long-term protection against cholera. Issues such as logistical and Political instability have been hampering the vaccine distribution in certain regions.
Various key trends, such as increasing emphasis on oral vaccines driven by their ease of administration in mass vaccination campaigns evolved the global cholera market. For more effective, long-lasting vaccines, investment in research is growing. Collaborative efforts between NGOs, governments and global health organisations are improving vaccine distribution in prevalent regions. Furthermore, advancements such as mobile clinics, digital and health solutions are contributing to the wider vaccine coverage. Trends such as increasing public awareness and policy changes are fueling more comprehensive cholera prevention strategies.
The global cholera vaccine Industry offers promising investment opportunities in developing cost-effective oral vaccines and refining vaccine production technologies. In underserved regions, both NGOs and government bodies can expand the potential of distribution networks. Investors can explore R&D for vaccines with longer-lasting immunity to meet gaps in existing offerings. Furthermore, the growth is also expanding as the digital health platforms for vaccination and monitoring. Investors can also explore sustainable vaccine initiatives and public-private partnerships, while cholera prevention becomes a global concern.
Leading players supporting research efforts and vaccine distribution to battle cholera in the global cholera vaccine market include multinational pharmaceutical companies like Sanofi, Valneva SE, and PaxVax, along with global health organisations such as the World Health Organisation (WHO).
The government plays a crucial role in the global cholera vaccine market. Governments have been launching various regulations globally to ensure efficacy, vaccine safety, and quality control. Regulatory bodies such as the FDA and EMA focus on clinical trials and vaccine approval processes. In endemic regions, international organisations such as the World Health Organisation (WHO) are driving international standards for cholera vaccine use. Governments also set standards on vaccine pricing, distribution, and accessibility to safeguard equitable access, particularly in low-income countries. Furthermore, they introduce various emergency rules to meet cholera outbreaks swiftly and efficiently.
The global cholera vaccine market's future seems promising due to the rising awareness. Technological advancements in vaccines have been enhancing efficacy and accessibility. Oral vaccines may gain popularity in outbreak-prone areas, further supporting the growth. Vaccine distribution in underserved regions will be fueled by public-private partnerships and global health initiatives. Furthermore, longer-lasting protection and meeting numerous strains of cholera is driven by continuous research. As awareness and infrastructure improve, the market will evolve towards more sustainable and equitable cholera prevention solutions worldwide.
The report offers a comprehensive study of the subsequent market segments and their leading categories.
Governments are the dominant force in the global cholera vaccine market share as they play a crucial role in purchasing and distributing cholera vaccines, especially in countries with frequent outbreaks. Governments partner with international organisations like the World Health Organisation (WHO) and UNICEF to fund and implement vaccination programs in high-risk regions.
According to Mansi Kaushik, Senior Research Analyst, 6Wresearch, the Asia-Pacific region is the dominant in the global cholera vaccine market due to the high frequency of cholera outbreaks in countries like India, Bangladesh, Indonesia, and Nepal, where waterborne diseases are a significant health threat.
The market report provides a detailed analysis of the following market segments:
Global Cholera Vaccine Market |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Global Cholera Vaccine Market Overview |
3.1 Global Regional Macro Economic Indicators |
3.2 Global Cholera Vaccine Market Revenues & Volume, 2021 & 2031F |
3.3 Global Cholera Vaccine Market - Industry Life Cycle |
3.4 Global Cholera Vaccine Market - Porter's Five Forces |
3.5 Global Cholera Vaccine Market Revenues & Volume Share, By Regions, 2021 & 2031F |
3.6 Global Cholera Vaccine Market Revenues & Volume Share, By Product, 2021 & 2031F |
3.7 Global Cholera Vaccine Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 Global Cholera Vaccine Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Global Cholera Vaccine Market Trends |
6 Global Cholera Vaccine Market, 2021 - 2031 |
6.1 Global Cholera Vaccine Market, Revenues & Volume, By Product, 2021 - 2031 |
6.1.1 Overview & Analysis |
6.1.2 Global Cholera Vaccine Market, Revenues & Volume, By Dukoral, 2021 - 2031 |
6.1.3 Global Cholera Vaccine Market, Revenues & Volume, By Shanchol, 2021 - 2031 |
6.1.4 Global Cholera Vaccine Market, Revenues & Volume, By Vaxchora, 2021 - 2031 |
6.1.5 Global Cholera Vaccine Market, Revenues & Volume, By Euvichol & Euvichol-Plus, 2021 - 2031 |
6.1.6 Global Cholera Vaccine Market, Revenues & Volume, By Others, 2021 - 2031 |
6.2 Global Cholera Vaccine Market, Revenues & Volume, By End User, 2021 - 2031 |
6.2.1 Overview & Analysis |
6.2.2 Global Cholera Vaccine Market, Revenues & Volume, By Hospitals & clinics, 2021 - 2031 |
6.2.3 Global Cholera Vaccine Market, Revenues & Volume, By Research & Academic Laboratories, 2021 - 2031 |
6.2.4 Global Cholera Vaccine Market, Revenues & Volume, By Others, 2021 - 2031 |
6.3.1 Overview & Analysis |
7 North America Cholera Vaccine Market, Overview & Analysis |
7.1 North America Cholera Vaccine Market Revenues & Volume, 2021 - 2031 |
7.2 North America Cholera Vaccine Market, Revenues & Volume, By Countries, 2021 - 2031 |
7.2.1 United States (US) Cholera Vaccine Market, Revenues & Volume, 2021 - 2031 |
7.2.2 Canada Cholera Vaccine Market, Revenues & Volume, 2021 - 2031 |
7.2.3 Rest of North America Cholera Vaccine Market, Revenues & Volume, 2021 - 2031 |
7.3 North America Cholera Vaccine Market, Revenues & Volume, By Product, 2021 - 2031 |
7.4 North America Cholera Vaccine Market, Revenues & Volume, By End User, 2021 - 2031 |
8 Latin America (LATAM) Cholera Vaccine Market, Overview & Analysis |
8.1 Latin America (LATAM) Cholera Vaccine Market Revenues & Volume, 2021 - 2031 |
8.2 Latin America (LATAM) Cholera Vaccine Market, Revenues & Volume, By Countries, 2021 - 2031 |
8.2.1 Brazil Cholera Vaccine Market, Revenues & Volume, 2021 - 2031 |
8.2.2 Mexico Cholera Vaccine Market, Revenues & Volume, 2021 - 2031 |
8.2.3 Argentina Cholera Vaccine Market, Revenues & Volume, 2021 - 2031 |
8.2.4 Rest of LATAM Cholera Vaccine Market, Revenues & Volume, 2021 - 2031 |
8.3 Latin America (LATAM) Cholera Vaccine Market, Revenues & Volume, By Product, 2021 - 2031 |
8.4 Latin America (LATAM) Cholera Vaccine Market, Revenues & Volume, By End User, 2021 - 2031 |
9 Asia Cholera Vaccine Market, Overview & Analysis |
9.1 Asia Cholera Vaccine Market Revenues & Volume, 2021 - 2031 |
9.2 Asia Cholera Vaccine Market, Revenues & Volume, By Countries, 2021 - 2031 |
9.2.1 India Cholera Vaccine Market, Revenues & Volume, 2021 - 2031 |
9.2.2 China Cholera Vaccine Market, Revenues & Volume, 2021 - 2031 |
9.2.3 Japan Cholera Vaccine Market, Revenues & Volume, 2021 - 2031 |
9.2.4 Rest of Asia Cholera Vaccine Market, Revenues & Volume, 2021 - 2031 |
9.3 Asia Cholera Vaccine Market, Revenues & Volume, By Product, 2021 - 2031 |
9.4 Asia Cholera Vaccine Market, Revenues & Volume, By End User, 2021 - 2031 |
10 Africa Cholera Vaccine Market, Overview & Analysis |
10.1 Africa Cholera Vaccine Market Revenues & Volume, 2021 - 2031 |
10.2 Africa Cholera Vaccine Market, Revenues & Volume, By Countries, 2021 - 2031 |
10.2.1 South Africa Cholera Vaccine Market, Revenues & Volume, 2021 - 2031 |
10.2.2 Egypt Cholera Vaccine Market, Revenues & Volume, 2021 - 2031 |
10.2.3 Nigeria Cholera Vaccine Market, Revenues & Volume, 2021 - 2031 |
10.2.4 Rest of Africa Cholera Vaccine Market, Revenues & Volume, 2021 - 2031 |
10.3 Africa Cholera Vaccine Market, Revenues & Volume, By Product, 2021 - 2031 |
10.4 Africa Cholera Vaccine Market, Revenues & Volume, By End User, 2021 - 2031 |
11 Europe Cholera Vaccine Market, Overview & Analysis |
11.1 Europe Cholera Vaccine Market Revenues & Volume, 2021 - 2031 |
11.2 Europe Cholera Vaccine Market, Revenues & Volume, By Countries, 2021 - 2031 |
11.2.1 United Kingdom Cholera Vaccine Market, Revenues & Volume, 2021 - 2031 |
11.2.2 Germany Cholera Vaccine Market, Revenues & Volume, 2021 - 2031 |
11.2.3 France Cholera Vaccine Market, Revenues & Volume, 2021 - 2031 |
11.2.4 Rest of Europe Cholera Vaccine Market, Revenues & Volume, 2021 - 2031 |
11.3 Europe Cholera Vaccine Market, Revenues & Volume, By Product, 2021 - 2031 |
11.4 Europe Cholera Vaccine Market, Revenues & Volume, By End User, 2021 - 2031 |
12 Middle East Cholera Vaccine Market, Overview & Analysis |
12.1 Middle East Cholera Vaccine Market Revenues & Volume, 2021 - 2031 |
12.2 Middle East Cholera Vaccine Market, Revenues & Volume, By Countries, 2021 - 2031 |
12.2.1 Saudi Arabia Cholera Vaccine Market, Revenues & Volume, 2021 - 2031 |
12.2.2 UAE Cholera Vaccine Market, Revenues & Volume, 2021 - 2031 |
12.2.3 Turkey Cholera Vaccine Market, Revenues & Volume, 2021 - 2031 |
12.3 Middle East Cholera Vaccine Market, Revenues & Volume, By Product, 2021 - 2031 |
12.4 Middle East Cholera Vaccine Market, Revenues & Volume, By End User, 2021 - 2031 |
13 Global Cholera Vaccine Market Key Performance Indicators |
14 Global Cholera Vaccine Market - Export/Import By Countries Assessment |
15 Global Cholera Vaccine Market - Opportunity Assessment |
15.1 Global Cholera Vaccine Market Opportunity Assessment, By Countries, 2021 & 2031F |
15.2 Global Cholera Vaccine Market Opportunity Assessment, By Product, 2021 & 2031F |
15.3 Global Cholera Vaccine Market Opportunity Assessment, By End User, 2021 & 2031F |
16 Global Cholera Vaccine Market - Competitive Landscape |
16.1 Global Cholera Vaccine Market Revenue Share, By Companies, 2024 |
16.2 Global Cholera Vaccine Market Competitive Benchmarking, By Operating and Technical Parameters |
17 Top 10 Company Profiles |
18 Recommendations |
19 Disclaimer |